Compare Organon & Co. Common Stock (OGN) vs Oxford Lane Capital Corp (OXLC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Oxford Lane Capital Corp — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while Oxford Lane Capital Corp trades at $8.22 (market cap $817.57M). The key difference: Organon & Co. Common Stock is far larger — about 4.4× Oxford Lane Capital Corp's market cap, and Oxford Lane Capital Corp pays the higher dividend (28.78%). Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Oxford Lane Capital Corp for 51 Days on average.
| OGN | OXLC | |
|---|---|---|
Market Cap | $3.62B | $817.57M |
Volume | 2,892,999 | 2,300,089 |
Sector | Health | Financials |
52-Week High | $13.81 | $16.02 |
52-Week Low | $5.70 | $8.15 |
Typical Hold Time | 0 Days | 51 Days |
Enterprise Value | $11.04B | $1.21B |
Dividend Yield | 0.58% | 28.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
OXLC trades at $8.34, down 3.02% on the day, with a bearish technical outlook and weak earnings performance. Recent quarters show significant EPS misses, including a -$6.23 actual versus $2.26 expected in Q1 2026. The company maintains a high dividend payout of $0.20 monthly, but negative ROE and ROA highlight profitability challenges. Net asset value updates indicate substantial unrealized losses, with revenue turning negative in 2026.
The outlook is cautious due to deteriorating fundamentals and high payout ratios exceeding sustainable levels. Investment opportunities exist for yield-seeking investors attracted to the deep discount to NAV, but risks include persistent earnings volatility, reliance on financing for cash flow, and competitive pressures in the CLO space. Analyst sentiment is mixed, with 50% buy ratings offset by bearish technical signals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Oxford Lane Capital Corp
Oxford Lane Capital Corp. is a non-diversified, closed-end management investment company. Its primary investment objective is to achieve high current income, with a secondary objective of capital appreciation. The company primarily invests in equity and junior debt tranches of collateralized loan obligations (CLOs), which are pools of corporate loans. OXLC is known for its high-yield distribution policy and provides investors with leveraged exposure to the CLO market.
Read more on OXLC →
